The therapeutic effect of FTY720 on lupus nephritis in autoimmune MRL/lpr mice

被引：0
|
作者：
Sugahara, K [1 ]
Kataoka, H [1 ]
Ohtsuki, M [1 ]
Hoshino, Y [1 ]
Chiba, K [1 ]
机构：
[1] Mitsubishi Pharma Corp, Res Lab 3, Pharmaceut Res Unit, Div Res & Dev, Yokohama, Kanagawa, Japan
来源：
IMMUNOLOGY 2004: AUTOIMMUNITY, GENETIC AND DEGENERATIVE DISORDERS, MALIGNANCIES, AND TRANSPLANTATION | 2004年
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Sphingosine 1-phosphate receptor agonist, FTY720 at oral doses of 0.03 to 1 mg/kg exhibited the prophylactic and therapeutic effect on lupus nephritis spontaneously developed in MRL/lpr mice. The therapeutical administration of FTY720 resulted in a decrease in the number of T cells, especially CD4(+) T cells, infiltrated into kidney as well as reduction of lymphocytes in blood. Moreover, the elevation of Th1 cytokine/chemokine mRNA expression was decreased in kidneys of FTY720-treated group. These results suggest that FTY720 decreases autoreactive Th1 cell infiltration into kidneys by reduction of circulating lymphocytes in blood, and thereby shows a marked therapeutic effect on progressing lupus nephritis of MRL/lpr mice.
引用
下载
收藏
页码：271 / 274
页数：4
相关论文
共 50 条
  • [21] Therapeutic effect of FTY720 on the clinical course of NZB/W F1 lupus-prone mice.
    Kamimura, T
    Okazaki, H
    Hirata, D
    Sato, H
    Kano, S
    Minota, S
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S393 - S393
  • [22] Intrathymic kidney cells delay the onset of lupus nephritis in MRL-lpr/lpr mice
    Bloom, RD
    O'Connor, T
    Cizman, B
    Kalluri, R
    Naji, A
    Madaio, MP
    INTERNATIONAL IMMUNOLOGY, 2002, 14 (08) : 867 - 871
  • [23] FTY720 AS A POTENTIAL THERAPEUTIC AGENT FOR GLIOBLASTOMA
    Estrada-Bernal, Adriana
    Van Brocklyn, James R.
    NEURO-ONCOLOGY, 2010, 12 : 121 - 121
  • [24] FTY720 (fingolimod) treatment suppresses autoimmune uveoretinitis
    Copland, D.
    Brinkmann, V.
    Nuesslein-Hildesheim, B.
    Anderson, K.
    Brigell, M.
    Liu, J.
    Nicholson, L.
    Dick, A.
    IMMUNOLOGY, 2010, 131 : 83 - 83
  • [25] SUCCESSFUL TREATMENT OF LUPUS NEPHRITIS IN MRL-LPR LPR MICE BY INHIBITING ORNITHINE DECARBOXYLASE
    GUNNIA, UB
    AMENTA, PS
    SEIBOLD, JR
    THOMAS, TJ
    KIDNEY INTERNATIONAL, 1991, 39 (05) : 882 - 890
  • [26] EFFECT OF A NOVEL IMMUNOSUPPRESSANT, FK506, ON SPONTANEOUS LUPUS NEPHRITIS IN MRL MPJ-LPR LPR MICE
    ENTANI, C
    IZUMINO, K
    IIDA, H
    FUJITA, M
    ASAKA, M
    TAKATA, M
    SASAYAMA, S
    NEPHRON, 1993, 64 (03): : 471 - 475
  • [27] CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice
    Wu, Xiaobei
    Guo, Jialong
    Ding, Rui
    Lv, Bin
    Bi, Liqi
    ACTA HISTOCHEMICA, 2015, 117 (08) : 732 - 737
  • [28] Abrogation of Lupus Nephritis in Somatic Hypermutation-Deficient MRL/lpr Mice
    Hao, Fengqi
    Tian, Miaomiao
    Feng, Yunpeng
    Quan, Chao
    Chen, Yixi
    Chen, Shuai
    Wei, Min
    JOURNAL OF IMMUNOLOGY, 2018, 200 (12): : 3905 - 3912
  • [29] Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice
    Miyazaki, T
    Ono, M
    Qu, WM
    Zhang, MC
    Mori, S
    Nakatsuru, S
    Nakamura, Y
    Sawasaki, T
    Endo, Y
    Nose, M
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (05) : 1510 - 1520
  • [30] Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice
    Tan, Hechang
    Zhao, Jijun
    Wang, Shuang
    Zhang, Lili
    Wang, Hongyue
    Huang, Bin
    Liang, Yingjie
    Yu, Xueqing
    Yang, Niansheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2012, 14 (04) : 401 - 409
12345